Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed this Current Report on Form 8-K on November 10, 2025. The filing discloses updates regarding the ELIMINATE-B Phase 1 clinical trial for PBGENE-HBV, an in vivo gene editing therapy targeting chronic Hepatitis B. The company announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial progress and does not contain financial statements. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
As of the October 31, 2025 data cutoff, the ELIMINATE-B study reported the following material developments:
- Study Status: Nine evaluable patients have been dosed across three ascending cohorts (0.2, 0.4, and 0.8 mg/kg), totaling 22 administered doses.
- Antiviral Activity: All treated patients exhibited measurable reductions in hepatitis B surface antigen (HBsAg), regardless of baseline levels (ranging from 370 to 11,813 IU/mL). Reductions were dose-dependent and durable.
- Cohort Specifics:
- Cohort 1 (0.2 mg/kg): One patient showed a durable ~50% HBsAg reduction 9 months post-dose.
- Cohort 2 (0.4 mg/kg): Patients achieved durable declines up to 66% following the third dose.
- Cohort 3 (0.8 mg/kg): Early reductions observed at 2 weeks; one patient showed a 64% decrease after two doses with HBsAg levels as low as 188 IU/mL.
- Molecular Evidence: A liver biopsy from a Cohort 2 patient confirmed ARCUS-mediated gene editing events (insertion/deletion edits) in viral DNA, marking the first direct molecular evidence of HBV viral gene editing in humans.
- Safety Profile: The therapy was well-tolerated with no dose-limiting toxicities. Adverse events were transient, generally resolving within 12 hours. Transient elevations in liver enzymes (ALT/AST) were observed but resolved quickly without liver dysfunction.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- The Company expects to complete all administrations in Cohort 3 and finalize data in the first quarter of 2026.
- Future plans include testing for a cure by stopping nucleos(t)ide analogues once HBsAg becomes undetectable or approaches undetectable levels sustainably.
- Additional cohorts are planned to evaluate a 4-week dosing interval.
- The Company intends to advance PBGENE-HBV into the Part 2 expansion phase of the ELIMINATE-B study to evaluate the optimized dose regimen in a larger patient population.
Risks and Contingencies:
The filing includes standard forward-looking statement disclaimers. Risks include the uncertainty of clinical trial outcomes, the potential for adverse events not yet observed, and the possibility that the therapy may not achieve the goal of cccDNA eradication or functional cure. The company references risk factors detailed in its 2024 Form 10-K and 2025 Form 10-Q filings.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for complete data tables and statistical significance.
- Review the upcoming webcast on November 11, 2025, for management's detailed commentary on the data.
- Monitor the first quarter of 2026 for the finalization of Cohort 3 data.
- Assess the timeline for the transition to the Part 2 expansion phase and the criteria for stopping nucleos(t)ide analogues.
- Check subsequent filings for any updates on the safety profile regarding the transient liver enzyme elevations.